https://www.youtube.com/embed/7YNmW7CSJIg
Hight lights of the con call
Divis Q3FY23 Earnings Conference Call highlights:
The company is experiencing double digit growth in some generic products and also receiving repeat orders from customers, which should augur well in the future
Generic margins took a larger hit as compared to the custom synthesis
Most of the growth for top generic products was in volume terms during the
period
Unit 3 facility at Kakinada has received necessary clearance from the
government. The management is on the verge of finalising the project and
product planning.
Raw material prices have slightly softened post Q3FY23. Logistic and freight
cost is improving both for air and sea mode
It intends to diversify the supply base to keep the supply chain stable
Exports during the quarter remained around 87%, where sales from Europe
and US came in at 70%
The company does not plan to enter the injectable business but plans to
invest in new technologies remains concrete
New projects coming up are mostly coming in from big pharma companies
Generic margins took a larger hit compared to custom synthesis
| Subscribe To Our Free Newsletter |
